BR112020020703A2 - Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 . - Google Patents
Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 . Download PDFInfo
- Publication number
- BR112020020703A2 BR112020020703A2 BR112020020703-9A BR112020020703A BR112020020703A2 BR 112020020703 A2 BR112020020703 A2 BR 112020020703A2 BR 112020020703 A BR112020020703 A BR 112020020703A BR 112020020703 A2 BR112020020703 A2 BR 112020020703A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- vedolizumab
- formulation
- vmab
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020020703A2 true BR112020020703A2 (pt) | 2021-01-12 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020020703-9A BR112020020703A2 (pt) | 2018-04-10 | 2019-04-10 | Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 . |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (https=) |
| EP (1) | EP3773696A4 (https=) |
| JP (1) | JP2021521171A (https=) |
| CN (1) | CN112292146A (https=) |
| AU (1) | AU2019251453A1 (https=) |
| BR (1) | BR112020020703A2 (https=) |
| CO (1) | CO2020013571A2 (https=) |
| SG (1) | SG11202009876TA (https=) |
| WO (1) | WO2019198101A1 (https=) |
| ZA (1) | ZA202006264B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| AU2019251452A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| US20240101679A1 (en) * | 2020-12-09 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
| US20240254237A1 (en) * | 2021-06-04 | 2024-08-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4717712A2 (en) * | 2021-12-27 | 2026-04-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| KR20250120995A (ko) | 2022-11-07 | 2025-08-11 | 업스트림 바이오, 인크. | 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| EP2170390B1 (en) * | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| KR101247418B1 (ko) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| WO2017015198A1 (en) | 2015-07-17 | 2017-01-26 | Coherus Biosciences, Inc. | Stable aqeous formulations of natalizumab |
| US20220267449A1 (en) | 2019-06-10 | 2022-08-25 | Takeda Pharmaceutical Company Limited | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY |
-
2019
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12433947B2 (en) | 2025-10-07 |
| CN112292146A (zh) | 2021-01-29 |
| CO2020013571A2 (es) | 2021-01-18 |
| EP3773696A1 (en) | 2021-02-17 |
| AU2019251453A1 (en) | 2020-11-26 |
| US20210401982A1 (en) | 2021-12-30 |
| ZA202006264B (en) | 2022-09-28 |
| SG11202009876TA (en) | 2020-11-27 |
| WO2019198101A1 (en) | 2019-10-17 |
| JP2021521171A (ja) | 2021-08-26 |
| EP3773696A4 (en) | 2021-12-29 |
| AU2019251453A2 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020020703A2 (pt) | Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 . | |
| BR112020020707A2 (pt) | Formulação farmacêutica estável de um anticorpo alfa4beta7 | |
| US11639391B2 (en) | Stable liquid pharmaceutical composition | |
| BR112015028411B1 (pt) | Formulações estáveis de domínios variáveis únicos de imunoglobulina e uso destas | |
| US20230340131A1 (en) | Stable aqueous high concentration formulation of integrin antibody | |
| CN114746439A (zh) | 整合蛋白抗体的稳定制剂 | |
| WO2024009205A1 (en) | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY | |
| EP4281045A1 (en) | Freeze dried antibody formulations and methods thereof | |
| BR112020020741A2 (pt) | Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. | |
| WO2025041000A1 (en) | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY | |
| US20240366757A1 (en) | Formulations of immune check point inhibitors or like | |
| US20220193238A1 (en) | Anti-il5r antibody formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |